Work

A Phase 2 biomarker-enriched study of evofosfamide (TH-302) in patients with advanced melanoma.

Year: 2015

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2015.33.15_suppl.tps9089

Authors: Elaine McWhirter, Omid Hamid, Bartosz Chmielowski, Richard D. Carvajal, David A. Jaffray, Brandon Driscoll, Tina Shek, Ivan Yeung, Harald Keller, Trevor D. McKee, Tillman E. Pearce, Stew Kroll, Anthony M. Joshua

Institutions: Juravinski Cancer Centre, Angeles Clinic and Research Institute, University of California, Los Angeles, Columbia University Irving Medical Center, Princess Margaret Cancer Centre, Threshold Pharmaceuticals (United States)

Language: English

Topic: Cutaneous Melanoma Detection and Management

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2598224365

Cites:

Cited by:

Related to: 10